Publications by authors named "Deborah N Wentworth"
Article Synopsis
- - The INSIGHT 006 trial tested Flu-IVIG, an antibody treatment, showing beneficial outcomes for patients with influenza B but not for those with influenza A.
- - Analysis of patient sera revealed that specific antibody types and their ability to bind to Fcγ receptors played a role in treatment effectiveness, with positive outcomes linked to higher FcγR-binding antibodies in influenza B patients.
- - The study emphasizes the importance of understanding antibody functionalities in improving treatments for influenza, indicating that targeted therapies could enhance patient outcomes, particularly for influenza B infections.
Influenza virus defective interfering (DI) particles are naturally occurring noninfectious virions typically generated during in vitro serial passages in cell culture of the virus at a high multiplicity of infection. DI particles are recognized for the role they play in inhibiting viral replication and for the impact they have on the production of infectious virions. To date, influenza virus DI particles have been reported primarily as a phenomenon of cell culture and in experimentally infected embryonated chicken eggs.
View Article and Find Full Text PDFBackground: To determine the impact of HIV-1 drug resistance at baseline and antiretroviral drug levels (DL) during follow-up on virologic response to the next antiretroviral regimen.
Methods: Baseline genotypic and phenotypic susceptibility was obtained for plasma virus from patients failing a protease inhibitor-containing regimen. Untimed plasma antiretroviral DL were performed and the distribution of DL after 12 weeks of follow-up was classified as above (DLHigh) or below (DLLow) the median.